Description

Cagrisema Vial — Combined GLP-1 and Amylin Receptor Research Peptide (12mg)

What is Cagrisema?

Cagrisema is a dual-formulation research peptide that combines a GLP-1 (glucagon-like peptide-1) receptor agonist with a long-acting amylin analogue in a single preparation. This combination approach to multi-receptor research represents an evolution in metabolic peptide studies — rather than studying each pathway in isolation, Cagrisema enables researchers to investigate how the incretin and amylin signalling systems interact simultaneously.

The GLP-1 component targets the well-characterised incretin receptor pathway involved in appetite regulation, gastric function, and glucose-dependent hormone secretion. The amylin component complements this by targeting the separate but related satiety signalling system mediated through the area postrema and brainstem. Together, these two mechanisms engage both peripheral and central signalling pathways.

Dual-Mechanism Research Rationale

Studying GLP-1 and amylin receptor pathways in combination is of research interest because these two systems operate through distinct but complementary mechanisms:

• GLP-1 Pathway: Acts primarily through hypothalamic and vagal nerve signalling, influencing appetite regulation, slowing gastric emptying, and promoting glucose-dependent hormone secretion via pancreatic beta cell GLP-1R activation.
• Amylin Pathway: Acts primarily through the area postrema (a circumventricular organ in the brainstem), signalling satiety and complementing GLP-1’s effects on gastric function. Amylin also influences renal handling of nutrients.
• Complementary Interaction: The two pathways target overlapping but non-identical tissue sites and signalling cascades, potentially producing additive or synergistic effects on metabolic signalling that cannot be observed with single-pathway research tools.

Research Applications

• Multi-Pathway Signalling Studies: Investigating how simultaneous GLP-1R and AMYR activation influences downstream cellular signalling.
• Satiety Mechanism Research: Studying the interaction between hypothalamic GLP-1 pathways and brainstem amylin pathways in appetite regulation.
• Gastric Function Studies: Examining combined effects on gastric emptying, gut motility, and gastrointestinal peptide signalling.
• Comparative Pharmacology: Comparing dual-pathway versus single-pathway effects to identify pathway-specific signalling outcomes.

Product Description

Each vial contains 12mg of lyophilised Cagrisema dual-formulation peptide in sterile, freeze-dried form. The peptide preparation is provided in a sealed glass vial with rubber stopper and aluminium crimp seal. The lyophilised cake or powder is white to off-white in appearance.

Manufactured under controlled laboratory conditions with quality verification. The dual-peptide formulation requires reconstitution prior to use in research protocols.

Product Specifications

• Formulation: Combined GLP-1 Receptor Agonist + Long-Acting Amylin Analogue
• Quantity: 12mg per vial (combined active content)
• Purity: ≥98% (HPLC verified)
• Form: Lyophilised sterile powder preparation
• Packaging: Individually sealed, sterile glass vial
• Storage: 2-8°C (refrigerated). Protect from light and moisture.

Handling Notes

For experienced research personnel. Use appropriate PPE. Reconstitute with sterile diluent for research use. Gently swirl to dissolve — avoid vigorous agitation. Use within recommended timeframe after reconstitution and store at 2-8°C.

What’s Included

Each order includes 1 × 3ml Bacteriostatic Water (BAC Water) for reconstituting the lyophilised powder. No additional reconstitution solution is required.

Key Research Benefits

• GLP-1 + Amylin Dual Pathway: Complementary incretin and amylin signalling in one vial.
• Satiety Mechanism Research: Hypothalamic GLP-1 and brainstem amylin pathways studied together.
• Gastric Function Studies: Combined effects on gastric emptying and gut motility research.
• Synergy Investigation: Additive or synergistic metabolic signalling vs single-pathway tools.

Important Notice

This product is for research and laboratory purposes only. Not for human or veterinary consumption. Not for medical use. Not evaluated by SAHPRA. Information is educational reference only. Researchers must comply with all applicable laws, regulations, and institutional research guidelines.